Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | TP53 wild-type |
| Therapy | SAR405838 |
| Indication/Tumor Type | salivary gland adenoid cystic carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 wild-type | salivary gland adenoid cystic carcinoma | predicted - sensitive | SAR405838 | Preclinical - Pdx | Actionable | In a preclinical study, treatment with SAR405838 (MI-773) resulted in activation of Mdm2 and Tp53 in patient-derived salivary gland adenoid cystic carcinoma (ACC) cells in culture, and led to induction of apoptosis and tumor regression in ACC patient-derived xenograft (PDX) models with wild-type TP53 (PMID: 26936915). | 26936915 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26936915) | Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. | Full reference... |